{"brief_title": "A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B", "brief_summary": "This study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) with Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the treatment of hepatitis B infection. The results for patients taking LdT will be compared to results for patients taking Lamivudine.", "condition": ["Chronic Hepatitis B"], "intervention_type": ["Drug"], "intervention_name": ["telbivudine or lamivudine"], "criteria": "Inclusion Criteria: - Chronic Hepatitis B, documented by Clinical history compatible with chronic HBV Other protocol-defined inclusion criteria may apply. Exclusion Criteria: - Patient is pregnant or breastfeeding - Patient is co infected with hepatitis C virus (HCV), hepatitis D virus (HDV), HIV-1 or HIV-2. - Patient previously received lamivudine or an investigational anti-HBV nucleoside or nucleotide analog at any time - Patient has received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study Other protocol defined exclusion criteria may apply.", "gender": "All", "minimum_age": "16 Years", "maximum_age": "70 Years", "mesh_term": ["Hepatitis", "Hepatitis A", "Hepatitis, Chronic", "Hepatitis B", "Hepatitis B, Chronic", "Telbivudine", "Lamivudine"], "id": "NCT00057265"}